remibrutinib

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Autoimmune and Chronic Inflammatory Diseases

Conditions

Autoimmune and Chronic Inflammatory Diseases

Trial Timeline

Jul 23, 2025 → Oct 14, 2025

NCT ID

NCT07032272

About remibrutinib

remibrutinib is a phase 1 stage product being developed by Novartis for Autoimmune and Chronic Inflammatory Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT07032272. Target conditions include Autoimmune and Chronic Inflammatory Diseases.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05170724	Pre-clinical	Active	—	—	Chronic Spontaneous Urticaria
NCT07456891	Phase 3	Recruiting	Apr 10, 2026	Jan 30, 2033	Indication of the Parent Protocol
NCT07032272	Phase 1	Completed	Jul 23, 2025	Oct 14, 2025	Autoimmune and Chronic Inflammatory Diseases
NCT05976243	Phase 3	Active	Dec 7, 2023	Jun 15, 2029	Chronic Inducible Urticaria

Competing Products

20 competing products in Autoimmune and Chronic Inflammatory Diseases

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	77
SHR0302 quick release tablets + SHR0302 sustained-release tablets	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	33
HR19042 Capsules	Jiangsu Hengrui Medicine	Phase 2	52
Enteric-coated Mycophenolate Sodium	Novartis	Phase 3	77
Ianalumab + Placebo	Novartis	Phase 3	77
VAY736	Novartis	Phase 2/3	65
RO7049665	Roche	Phase 2	52
rituximab (Mabthera®) + Placebo	Roche	Phase 3	77
NovoMix 30 + Tablet treatment	Novo Nordisk	Pre-clinical	22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)	Swedish Orphan Biovitrum	Phase 2	51
branebrutinib + abatacept + branebrutinib placebo	Bristol Myers Squibb	Phase 2	51
BMS-986165	Bristol Myers Squibb	Phase 1	32
Nivolumab	Bristol Myers Squibb	Phase 1	32
Fludarabine + Cyclophosphamide + Tocilizumab	Bristol Myers Squibb	Phase 1	32
BMS-986165 + Rosuvastatin	Bristol Myers Squibb	Phase 1	32
SAR445088	Sanofi	Phase 1	32
BIVV020	Sanofi	Phase 1	32
rilzabrutinib	Sanofi	Phase 2	51
rilzabrutinib + placebo	Sanofi	Phase 3	76

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved